Friday, June 2, 2023, Chicago, Illinois, 6:30 PM – 9:00 PM Central Time (7:30 PM – 10:00 PM Eastern Time)

Video Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Non-Small Cell Lung Cancer

A CME Hybrid Symposium Held in Conjunction with the 2023 ASCO Annual Meeting

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Program Schedule — Central Time
6:00 PM – 6:30 PM — Registration and Dinner
6:30 PM – 9:00 PM — Educational Meeting

Meeting Room
Grand Ballroom (Level 2)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  
 
Faculty
Edward B Garon, MD, MS
Professor
Director, Thoracic Oncology Program
Director, Signal Transduction and Therapeutics Research Program
David Geffen School of Medicine at UCLA
Jonsson Comprehensive Cancer Center
Los Angeles, California

John V Heymach, MD, PhD
Professor and Chair
Thoracic/Head and Neck Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Corey J Langer, MD
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania


Ticiana Leal, MD
Associate Professor
Department of Hematology and Oncology
Director, Thoracic Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

David R Spigel, MD
Chief Scientific Officer
Sarah Cannon Research Institute
Nashville, Tennessee

Helena Yu, MD
Medical Oncologist
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, New York

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, Novocure Inc, Regeneron Pharmaceuticals Inc, and Takeda Pharmaceuticals USA Inc.
Program Schedule — Central Time
6:00 PM – 6:30 PM — Registration and Dinner Buffet
6:30 PM – 9:00 PM — Educational Meeting

MODULE 1: Incorporation of Immunotherapeutic Strategies into the Management of Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) — Dr Heymach

  • Key findings from the Phase III CheckMate 816 trial evaluating nivolumab in combination with chemotherapy as neoadjuvant therapy for patients with resectable Stage IB to IIIA NSCLC
  • Recent FDA approval of neoadjuvant nivolumab; selection of patients for this therapy
  • Recently presented data from the Phase III AEGEAN study of neoadjuvant durvalumab and chemotherapy followed by adjuvant durvalumab for patients with resectable NSCLC
  • Emerging findings from the Phase III KEYNOTE-671 study of pembrolizumab/platinum-based chemotherapy followed by resection and pembrolizumab for localized NSCLC
  • Published findings from the Phase III IMpower010 trial evaluating atezolizumab versus best supportive care after adjuvant chemotherapy for patients with completely resected NSCLC; impact of PD-L1 status on outcomes
  • Key efficacy and safety data from the Phase III PEARLS/KEYNOTE-091 study of pembrolizumab as adjuvant therapy for Stage IB to IIIA NSCLC
  • FDA approval of atezolizumab and pembrolizumab as adjuvant therapy; current clinical roles
  • Long-term efficacy and safety findings, including 5-year overall survival data, from the Phase III PACIFIC trial evaluating consolidation durvalumab after chemoradiation therapy for patients with unresectable Stage III NSCLC

MODULE 2: Contemporary Treatment for Localized or Metastatic NSCLC with an EGFR Mutation — Dr Yu

  • Key efficacy and safety findings, including emerging overall survival data, from the Phase III ADAURA trial evaluating adjuvant osimertinib for patients with Stage IB to IIIA NSCLC with EGFR mutations; appropriate incorporation into clinical care
  • Ongoing Phase III evaluation of osimertinib for nonmetastatic NSCLC, such as in the NeoADAURA and LAURA trials; nonresearch role, if any
  • Optimal selection of first-line treatment for patients with metastatic NSCLC and EGFR tumor mutations, including those with CNS metastases
  • Incidence, clinical relevance and spectrum of resistance mechanisms in patients receiving osimertinib
  • Published findings (eg, from the SAVANNAH trial) with and ongoing studies (eg, the SAFFRON and ORCHARD trials) of osimertinib combined with other agents for patients experiencing disease progression on first-line osimertinib
  • Mechanism of action of the novel HER3-directed antibody-drug conjugate patritumab deruxtecan; available data, ongoing evaluation and potential clinical role in metastatic EGFR tyrosine kinase inhibitor-resistant NSCLC
  • Antitumor activity and tolerability of amivantamab/lazertinib in the CHRYSALIS-2 study for patients with progressive NSCLC with EGFR mutations
  • Key efficacy and safety findings informing the FDA approvals of amivantamab and mobocertinib for patients with metastatic NSCLC and EGFR exon 20 mutations; appropriate selection and sequencing of these agents

MODULE 3: Research Advances Shaping the Current and Future Treatment of Metastatic NSCLC with ALK Rearrangements, ROS1 Rearrangements or RET Fusions — Dr Langer

  • Published data with alectinib, brigatinib or lorlatinib as first-line therapy for patients with NSCLC and ALK rearrangements; clinical factors in the selection of which to administer
  • Differential CNS permeability and intracranial response rates observed with approved ALK-targeted agents; implications for selection of treatment for patients with brain metastases
  • Indications for and implications of repeat biomarker testing for patients with progressive NSCLC with ALK rearrangements; selection of therapy for disease that is progressing on first-line ALK inhibition
  • Principal efficacy and safety findings with entrectinib for NSCLC with a ROS1 rearrangement; integration into clinical practice
  • Available data with, FDA breakthrough therapy designation for and ongoing evaluation of repotrectinib for NSCLC with a ROS1 rearrangement
  • Key efficacy and safety results with selpercatinib or pralsetinib for patients with RET fusion-driven NSCLC, including those with previously untreated disease; optimal integration into therapy and selection between these agents
  • Appropriate sequencing of immunotherapy for patients with metastatic NSCLC and targetable tumor mutations, including ALK, ROS1 and RET alterations

MODULE 4: Targeting MET, HER2 and KRAS Alterations in NSCLC — Dr Spigel

  • Key efficacy and safety findings with capmatinib or tepotinib for patients with NSCLC with MET exon 14 mutations; current clinical role and practical implementation
  • Clinical activity observed with commercially available MET inhibitors in patients with high-level MET amplification
  • Mechanism of action of telisotuzumab vedotin; available efficacy and safety findings with telisotuzumab vedotin for NSCLC with c-MET overexpression
  • Available efficacy and safety outcomes from the Phase II DESTINY-Lung02 study evaluating trastuzumab deruxtecan (T-DXd) for previously treated NSCLC with a HER2 mutation
  • Recent FDA approval of T-DXd and current role in therapy for HER2-mutated disease
  • Efficacy outcomes with T-DXd for HER2-overexpressing NSCLC; potential role in this setting
  • Principal efficacy and safety findings with sotorasib or adagrasib for patients with previously treated NSCLC with a KRAS G12C mutation

MODULE 5: Current Management of Metastatic NSCLC without a Targetable Tumor Mutation — Dr Garon

  • Key factors in the selection of anti-PD-1/PD-L1 monotherapy, combined chemoimmunotherapy or dual immune checkpoint inhibition with or without chemotherapy for patients with newly diagnosed metastatic NSCLC without a targetable tumor mutation
  • Clinical trial database supporting the FDA approvals of pembrolizumab, atezolizumab and cemiplimab administered as monotherapy for the first-line treatment of metastatic NSCLC
  • Major findings from clinical trials evaluating various combinations of pembrolizumab and atezolizumab with chemotherapy as first-line treatment for advanced NSCLC
  • Key results from the Phase III EMPOWER-Lung 3 study of first-line cemiplimab in combination with platinum-based chemotherapy; recent FDA approval and current clinical role
  • Long-term follow-up from the Phase III CheckMate 227 and CheckMate 9LA trials evaluating first-line nivolumab/ipilimumab with and without chemotherapy for metastatic NSCLC; patient selection for these strategies
  • Principal efficacy and safety findings from the Phase III POSEIDON trial evaluating durvalumab or durvalumab and tremelimumab in combination with platinum-based chemotherapy versus chemotherapy alone as first-line therapy for patients with metastatic NSCLC
  • Recent FDA approval of durvalumab/tremelimumab/chemotherapy and current role in clinical practice

MODULE 6: Future Directions in the Management of Metastatic NSCLC — Dr Leal

  • Biologic rationale for targeting TROP2 in lung cancer; mechanism of action of the TROP2-directed antibody-drug conjugate datopotamab deruxtecan (dato-DXd)
  • Clinical activity observed with dato-DXd as monotherapy and in combination with other systemic anticancer therapies for advanced NSCLC; ongoing Phase III studies
  • Incidence and severity of toxicities associated with dato-DXd, including interstitial lung disease
  • Mechanism of action of tumor treating fields; preclinical and early clinical data supporting the investigation of this treatment modality in NSCLC
  • Emerging positive results from the Phase III LUNAR study of tumor treating fields concurrent with immune checkpoint inhibition or docetaxel for metastatic NSCLC after failure of platinum-based therapy
  • Potential clinical role of tumor treating fields in the care of patients with progressive NSCLC
  • Early-phase data with anti-PD-1/PD-L1 antibodies in combination with other systemic therapies (eg, ramucirumab/pembrolizumab, lenvatinib/pembrolizumab, sitravatinib/nivolumab, durvalumab/ceralasertib) for progressive advanced NSCLC
  • Other promising novel agents and strategies in clinical development for advanced NSCLC

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Evaluate available and emerging data documenting the efficacy and safety of anti-PD-1/PD-L1 antibody-based approaches as neoadjuvant, adjuvant or consolidation therapy for nonmetastatic non-small cell lung cancer (NSCLC).
  • Acknowledge the FDA approval of adjuvant EGFR tyrosine kinase inhibitor therapy for localized NSCLC with an EGFR mutation, and identify patients for whom this treatment would be warranted.
  • Counsel patients with metastatic NSCLC with EGFR mutations about available therapeutic options.
  • Understand the biology of EGFR exon 20 insertion mutations, and evaluate how recently approved agents should be used in the care of patients with these abnormalities.
  • Assess the efficacy and safety of commercially available and investigational therapies for patients with metastatic NSCLC with ALK or ROS1 rearrangements, and use this information to select first- and later-line therapy.
  • Recollect other oncogenic pathways mediating the pathogenesis of tumors (ie, RET, MET, HER2 and KRAS G12C), and recall published data with agents exploiting these targets.
  • Review recent therapeutic advances related to the use of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy, chemobiologic therapy or anti-CTLA-4 antibodies for metastatic NSCLC, and discern how these approaches can be optimally employed in clinical practice.
  • Reflect on investigational agents and strategies currently in testing for lung cancer, and appropriately refer eligible patients for clinical trial participation.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Garon — Consulting Agreements: ABL Bio, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Dracen Pharmaceuticals, Eisai Inc, EMD Serono Inc, Gilead Sciences Inc, GSK, Lilly, Merck, Natera Inc, Novartis, Personalis, Regeneron Pharmaceuticals Inc, Sanofi, Shionogi Inc, Xilio Therapeutics, Zymeworks Inc; Contracted Research: ABL Bio, AstraZeneca Pharmaceuticals LP, BioNTech SE, Bristol Myers Squibb, Daiichi Sankyo Inc, Dynavax Technologies, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, lovance Biotherapeutics, Lilly, Merck, Mirati Therapeutics Inc, Novartis; Data and Safety Monitoring Board/Committee: Nuvalent; Sponsored Independent Medical Education: Daiichi Sankyo Inc, Ipsen Biopharmaceuticals Inc; Travel: A2 Bio, Novartis. Dr Heymach — Advisory Committee: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, BrightPath Biotherapeutics Co Ltd, Bristol Myers Squibb, Catalyst Pharmaceuticals, Chugai Pharmaceutical Co Ltd, EMD Serono Inc, Genentech, a member of the Roche Group, GSK, Hengrui Therapeutics Inc, Janssen Biotech Inc, Lilly, Mirati Therapeutics Inc, Nexus Health Systems, Pneuma Respiratory, RefleXion, Sanofi, Spectrum Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Research Support: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Spectrum Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Royalties and Licensing Fees: Spectrum Pharmaceuticals Inc. Dr Langer — Consulting Fees: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Heat Biologics, Merck, Mirati Therapeutics Inc, Novocure Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Data Safety Monitoring Board or Advisory Board (Co-Chair): Amgen Inc, Oncocyte; Medical Writing: Novartis; Research Funding: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Inovio Pharmaceuticals Inc, Lilly, Merck, Oncocyte, Takeda Pharmaceuticals USA Inc, Trizell; Nonrelevant Financial Relationship: US Department of Veterans Affairs. Dr Leal — Consultant/Advisory Boards: Amgen Inc, AstraZeneca Pharmaceuticals LP, Catalyst Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Merck, Novocure Inc, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Advaxis Inc, Bayer HealthCare Pharmaceuticals, Pfizer Inc; Data and Safety Monitoring Board/Committee: OncoC4; Speaker: Aptitude Health, Cardinal Health, Curio Bioscience; Nonrelevant Financial Relationship: ASTRO, GASCO, GRACE, IDEOlogy Health, Medscape, National Cancer Institute, Nebraska Oncology Society, OncLive, Opinions in Lung Cancer, PeerView, SITC, Targeted Oncology. Dr Spigel — Consulting Agreements (to Institution): Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Curio Science, EMD Serono Inc, Evidera, Exelixis Inc, Genentech, a member of the Roche Group, GSK, Intellisphere LLC, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Mirati Therapeutics Inc, Molecular Templates, Novartis, Novocure Inc, Pfizer Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research (to Institution): Aeglea BioTherapeutics, Agios Pharmaceuticals Inc, Apollomics Inc, Arcus Biosciences, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BIND Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, Clovis Oncology, Cyteir Therapeutics, Daiichi Sankyo Inc, Denovo Biopharma, Eisai Inc, Elevation Oncology, EMD Serono Inc, Evelo Biosciences Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, GSK, Grail Inc, Hutchison MediPharma, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kronos Bio, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MacroGenics Inc, Merck, Molecular Partners, Molecular Templates, Nektar, Neon Therapeutics, Novartis, Novocure Inc, OncXerna Therapeutics Inc, Pfizer Inc, PTC Therapeutics, PureTech Health, Razor Genomics, Repare Therapeutics, Rgenix, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Tizona Therapeutics Inc, Transgene, UT Southwestern Medical Center, Verastem Inc. Dr Yu — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Blueprint Medicines, C4 Therapeutics, Cullinan Oncology, Daiichi Sankyo Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Janssen Biotech Inc; Research Funding to My Institution: AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Blueprint Medicines, Cullinan Oncology, Daiichi Sankyo Inc, Erasca, Janssen Biotech Inc, Novartis, Pfizer Inc.

CONTRIBUTING INVESTIGATORS — Matthew Gubens, MD, MS — Consulting Agreements: AnHeart Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Cardinal Health, Genentech, a member of the Roche Group, Genzyme Corporation, Gilead Sciences Inc, Guardant Health, iTeos Therapeutics, Sanofi, Summit Therapeutics, Surface Oncology; Contracted Research (Funding to Institution as Site PI): Amgen Inc, Celgene Corporation, Johnson & Johnson Pharmaceuticals, Merck, Novartis, OncoMed Pharmaceuticals Inc, Trizell. Melissa Johnson, MD — Consulting Agreements: AbbVie Inc, Amgen Inc, Arcus Biosciences, ArriVent Biopharma, Astellas, AstraZeneca Pharmaceuticals LP, Axelia Oncology, Black Diamond Therapeutics Inc, Calithera Biosciences, Daiichi Sankyo Inc, EcoR1 Capital LLC, Genentech, a member of the Roche Group, Genmab US Inc, Genocea, Gritstone bio, GSK, IDEAYA Biosciences, Immunocore, iTeos Therapeutics, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Merck, Mirati Therapeutics Inc, Molecular Axiom, Novartis, Oncorus, Pyramid Biosciences, Regeneron Pharmaceuticals Inc, Revolution Medicines, Sanofi, Seagen Inc, Synthekine, Takeda Pharmaceuticals USA Inc, Turning Point Therapeutics Inc, VBL Therapeutics; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptimmune, Amgen Inc, Apexigen, Arcus Biosciences, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Atreca, BeiGene Ltd, BerGenBio ASA, BioAtla, Birdie Biopharmaceuticals, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Calithera Biosciences, Carisma Therapeutics, Checkpoint Therapeutics Inc, Corvus Pharmaceuticals, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dracen Pharmaceuticals, Dynavax Technologies, Elicio Therapeutics, EMD Serono Inc, EQRx, Erasca, Exelixis Inc, Fate Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc, Genocea, Gritstone bio, GSK, Guardant Health, Harpoon Therapeutics, Helsinn Healthcare SA, Hengrui Therapeutics Inc, Hutchison MediPharma, IDEAYA Biosciences, Immunitas Therapeutics, Immunocore, Incyte Corporation, Janssen Biotech Inc, Jounce Therapeutics, Kadmon, Kartos Therapeutics, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lycera, Merck, Merus BV, Mirati Therapeutics Inc, Mythic Therapeutics, NeolummuneTech, Neovia Oncology, Novartis, Nuvalent, OncoMed Pharmaceuticals Inc, Palleon Pharmaceuticals, Pfizer Inc, PMV Pharma, Rain Therapeutics, Rascal Therapeutics, Regeneron Pharmaceuticals Inc, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Roivant Sciences Ltd, Rubius Therapeutics, Sanofi, Seven and Eight Biopharmaceuticals Inc, Shattuck Labs, Stemcentrx, Syndax Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc, Tarveda Therapeutics, TCR2 Therapeutics, Tempest Therapeutics, Tizona Therapeutics Inc, Tmunity Therapeutics, Turning Point Therapeutics Inc, Vyriad, WindMIL Therapeutics, Y-mAbs Therapeutics Inc; Nonrelevant Financial Relationship: City of Hope National Medical Center, Memorial Sloan Kettering Cancer Center, University of Michigan. Jarushka Naidoo, MB BCH, MHS — Advisory Committee and Consulting Agreements: AbbVie Inc, Amgen Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Daiichi Sankyo Inc, Elevation Oncology, Genentech, a member of the Roche Group, Kaleido Biosciences, Mirati Therapeutics Inc, NGM Biopharmaceuticals, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Amgen Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Mirati Therapeutics Inc, Pfizer Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Bristol Myers Squibb, Daiichi Sankyo Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, Novocure Inc, Regeneron Pharmaceuticals Inc, and Takeda Pharmaceuticals USA Inc.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Grand Ballroom (Level 2)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

 
This activity is intended for medical and radiation oncologists, hematologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of lung cancer.

​ ​ ​
IN-PERSON registration
Thank you for your interest in our CME program taking place in Chicago, IL. At this time online in-person preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THE PROGRAM AND WILL BE OFFERED ON A FIRST COME FIRST SERVCE BASIS. Our Onsite Registration Desk will be open at 6:00 PM Central Time on Friday, June 2. If you are interested in attending, please visit our registration desk located outside the Grand Ballroom (Level 2) of the Hilton Chicago hotel (720 South Michigan Avenue). ASCO offers complimentary shuttle service from the McCormick Place Convention Center to this hotel. Information on shuttle service is available on the 2023 ASCO Annual Meeting website. Please note: onsite registration does not guarantee meal service which will be based on availability.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Registration for live webcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

Not an official event of the 2023 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.